Skip to main content

News

Psoriatic Arthritis: EULAR 2026 Recap

Years of IL-17 vs. IL-23 debate in PsA finally got tested head-to-head: bimekizumab outperformed risankizumab on joint outcomes in the BE BOLD trial, while a GLP-1 combination study suggests weight and metabolic status are active drivers of PsA — not just comorbidities. This recap also digs into early signals that biologic choice may influence whether psoriasis progresses to PsA, and why some well-controlled patients are still in pain.

Seronegative RA Disease Activity (7.17.2026)

Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow.com.

ACR: Medicare Cuts for Physicians Highlight Need for Reform

ACR

The American College of Rheumatology (ACR) was disappointed that the proposed Medicare Physician Fee Schedule (MPFS) from the Centers for Medicare & Medicaid Services (CMS) once again included a serious cut to the conversion factor.

The Marriage between Gout and the Kidney

While the link between uric acid and gout was first described by Alfred Baring Garrod in the 1800s, the proof that uric acid might actually be the cause had to await the self-experimentation of two rheumatologists from the University of Pennsylvania. Given some comments that the presence of urate crystals in synovial fluid might just be a bystander phenomenon, they decided to inject monosodium urate crystals in one knee and water in the other, and both suffered severe attacks of gout in the urate crystal injected knee.

ACP Position Paper on Dietary Supplements

More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law lets supplements reach the market with no premarket safety evaluation, unlike drugs or food additives.

Gout in Minority Populations

Gout is the most common inflammatory arthritis, but its burden is not shared equally across populations. Recent research has revealed substantial racial and ethnic disparities in both who develops gout and the care patients receive. These differences reflect not only genetic susceptibility but also the substantial influence of social determinants of health, healthcare access, and environmental exposures.

Why Do Gout Flares Start at Night?

The striking propensity for gout flares to initiate at night has been recognised for centuries. In 1683, Thomas Sydenham famously observed that the typical patient "goes to bed and sleeps in good health" only to be awakened around 2:00 AM by excruciating pain.

Guidelines to Spot Cancer in High Risk Dermatomyositis

MedPage Today
International guidelines can help identify dermatomyositis patients with a particularly high risk for cancer, according to a retrospective single-center U.S. study.

Gout Imaging in Care

Gout is all about the crystals and the consequences of the disease are due to the inflammation they cause.

Saliva and Uric Acid Testing

A recent report from China reaffirms the potential utility of salivary uric acid (UA) testing  delivers smartphone-guided, enzyme-free gout screening at home for pennies per test.

Gout Cavalcade (7.10.2026)

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.

Do we need Better Strategies to Prevent Osteoporotic Fractures?

In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.

CAR-T Therapy: EULAR 2026 Conference Recap

CAR-T therapy in autoimmune disease is moving fast - but is it ready to move beyond specialized referral centers? This EULAR 2026 recap covers the mechanistic data, relapse biology, and access innovations shaping that answer.

FDA Delays Gout Drug NASP with Complete Response Letter

At the end of June, Sobi was awaiting an FDA decision on its Biologics License Application (BLA) for NASP (nanoencapsulated sirolimus plus pegadricase) for the treatment of adult patients with uncontrolled gout. On June 26, 2026, SOBI received a Complete Response Letter from the U.S. FDA that will delay a decision on NASP, pending the company's answer to questions regarding the drugs manufacturing at a 3rd party facility in China.

Problems with treatment adherence in the management of gout

Compared to common medical conditions such as hypertension, type 2 diabetes, hyperlipidemia or osteoporosis, where the reported drug adherence rates are between 50% to 70%, the drug adherence for gout is 37%.
×